Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > My Takeaways

<< Previous

Bullboard Posts

Next >>

Comment by IrishCanuckon Jan 11, 2021 2:54pm

154 Views

Post# 32268764

RE:RE:My Takeaways

Yea, I clearly have no idea if you can step up more than one rung on the ladder at a time, or if you need to go step by step. I think that's the biggest unknown but I wouldn't be surprised if you could just jump straight up to the NASDAQ.

But all taken together if Dan thinks the stock should be valued 2-4 times more than it currently is, they're encouraged by big institutions investing in them, they're taking steps to unify IP, they're making moves on OTC, I think hitting the $5USD is a slam dunk :) I hope that last section is just the lawyers covering themselves

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market